Cambridge, United Kingdom

Kim Schneider

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2021-2022

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Kim Schneider: Innovator in Phosphatase Inhibitor Research

Introduction

Kim Schneider is a prominent inventor based in Cambridge, GB, known for his significant contributions to the field of phosphatase inhibitors. With a total of four patents to his name, Schneider has made strides in developing methods that enhance the understanding and treatment of various diseases.

Latest Patents

One of Schneider's latest patents focuses on methods for selecting phosphatase selective and non-selective phosphatase inhibitors. This invention discloses a method to discover selective inhibitors of phosphatases. The method involves screening a test compound to determine whether it binds to a holophosphatase selectively or non-selectively. The process includes providing two different holophosphatases, testing the compound's binding ability to each, and comparing the results to identify selective binding. Another notable patent relates to inhibitors of PPP1 R15A and PPP1 R15B, which are crucial in therapies for diseases associated with the accumulation of misfolded proteins.

Career Highlights

Kim Schneider is affiliated with United Kingdom Research and Innovation, where he continues to advance his research in phosphatase inhibitors. His work has garnered attention for its potential therapeutic applications, particularly in treating disorders related to protein misfolding.

Collaborations

Schneider collaborates with esteemed colleagues, including Anne Bertolotti and Indrajit Das, who contribute to his research endeavors and enhance the impact of his innovations.

Conclusion

Kim Schneider's work in the field of phosphatase inhibitors exemplifies the importance of innovation in medical research. His patents not only advance scientific knowledge but also hold promise for future therapeutic developments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…